Switzerland-based healthcare business Lonza Group AG (LZAGF) on Tuesday confirmed its outlook for 2024 at flat sales growth in CER and Core EBITDA margin of high 20s. Sales in the second half of 2024 are expected to be solid, reflecting the timing of batch releases.
In its quarterly qualitative update, Lonza had reported a softer first quarter, with performance across the first half expected to align with the full-year 2024 trajectory.
The company also said that its key growth projects were progressing in line with plan. Operations are expected to commence at the large-scale Mammalian drug substance and highly potent API facilities in Visp in the fourth quarter of 2024. Construction is also on track at the large-scale commercial drug product facility in Stein.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.